Zacks: Analysts Expect Inovio Pharmaceuticals Inc (INO) to Post -$0.20 EPS

Equities research analysts predict that Inovio Pharmaceuticals Inc (NASDAQ:INO) will report ($0.20) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Inovio Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.29) and the highest is ($0.07). Inovio Pharmaceuticals reported earnings of ($0.08) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 150%. The firm is scheduled to announce its next earnings results on Tuesday, August 6th.

According to Zacks, analysts expect that Inovio Pharmaceuticals will report full-year earnings of ($1.01) per share for the current fiscal year, with EPS estimates ranging from ($1.06) to ($0.93). For the next financial year, analysts expect that the firm will report earnings of ($1.05) per share, with EPS estimates ranging from ($1.22) to ($0.93). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that follow Inovio Pharmaceuticals.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.01). The company had revenue of $2.83 million for the quarter, compared to analysts’ expectations of $4.44 million. Inovio Pharmaceuticals had a negative net margin of 295.24% and a negative return on equity of 97.95%.

Several equities analysts have issued reports on INO shares. HC Wainwright set a $13.00 price objective on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Monday, April 22nd. Cantor Fitzgerald started coverage on shares of Inovio Pharmaceuticals in a report on Monday, March 25th. They set an “overweight” rating and a $3.62 price objective on the stock. Maxim Group set a $8.00 price objective on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, February 20th. BidaskClub downgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, February 14th. Finally, Zacks Investment Research downgraded shares of Inovio Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, February 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $7.22.

INO opened at $2.39 on Friday. The company has a current ratio of 4.92, a quick ratio of 4.92 and a debt-to-equity ratio of 1.02. The firm has a market cap of $234.30 million, a price-to-earnings ratio of -2.28 and a beta of 1.70. Inovio Pharmaceuticals has a 52-week low of $2.36 and a 52-week high of $6.30.

In other Inovio Pharmaceuticals news, CEO Jong Joseph Kim sold 100,000 shares of the stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $3.31, for a total transaction of $331,000.00. Following the transaction, the chief executive officer now directly owns 2,411,055 shares of the company’s stock, valued at $7,980,592.05. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 7.90% of the company’s stock.

Several large investors have recently bought and sold shares of INO. Nikko Asset Management Americas Inc. purchased a new position in shares of Inovio Pharmaceuticals in the first quarter worth about $12,169,000. Sumitomo Mitsui Trust Holdings Inc. purchased a new position in shares of Inovio Pharmaceuticals in the first quarter worth about $11,896,000. ARK Investment Management LLC lifted its stake in shares of Inovio Pharmaceuticals by 55.4% in the first quarter. ARK Investment Management LLC now owns 2,929,597 shares of the biopharmaceutical company’s stock worth $10,927,000 after buying an additional 1,043,956 shares in the last quarter. D. E. Shaw & Co. Inc. lifted its stake in shares of Inovio Pharmaceuticals by 125.2% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,073,086 shares of the biopharmaceutical company’s stock worth $4,292,000 after buying an additional 596,684 shares in the last quarter. Finally, Defender Capital LLC. purchased a new position in shares of Inovio Pharmaceuticals in the fourth quarter worth about $2,324,000. 47.25% of the stock is currently owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Featured Story: Fiduciary

Get a free copy of the Zacks research report on Inovio Pharmaceuticals (INO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.